73

The vast diversity of mechanisms involved in oncogenesis and cancer progression accounts for the 96 percent failure rate observed among drug candidates in clinical trials and the lack of new therapeutic options. Orakl Oncology is a spin-off from the Gustave Roussy Institute of Oncology in France. This start-up aims to address the patient-specific complexity and heterogeneity of cancer early as possible in the drug development processes. The company has created a collection of “avatars” of patient tumors, which are used to predict how each patient will respond to future drugs. Orakl Oncology is an interdisciplinary biotechnology platform that combines best-in-class biology with high-grade clinical data and artificial intelligence to efficiently discover and optimize new treatments for the most suitable patients. Using this technology, Orakl Oncology works with hospitals and drug developers to provide patients with better and faster treatments.